NovaBay ophthalmology study begins in Brazil

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) has begun enrollment of patients in Brazil into its global Phase 2b clinical trial, BAYnovation, investigating Auriclosene ophthalmic solution as a treatment for adenoviral conjunctivitis, a highly contagious form of “pink eye” for which there is no approved treatment. The BAYnovation clinical study is expected to enroll about 450 patients [...]

NovaBay CEO interviewed on RedChip

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) chairman and CEO, Dr. Ron Najafi, was featured on the RedChip Money Report episode that aired on Fox Business on March 16. Dr. Najafi provided an overview of the company’s anti-infective programs and highlighted its three Phase 2 trials currently underway, studying lead Aganocide auriclosene in dermatology, ophthalmology, and urology. [...]

NovaBay blog post discusses crisis of antibiotic resistance

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) has published a comprehensive discussion on TheChairmansBlog.com, addressing the issue of antimicrobial resistance. TheChairmansBlog.com is an online media publication that enables key executives a unique platform to share insights about their company and industry trends. NovaBay chairman and CEO, Dr. Ron Najafi, explains the history of bacteria and how they have grown [...]

NovaBay names Keith Bley SVP product development

Tweet Keith Bley has joined NovaBay Pharmaceuticals (NYSE MKT:NBY) as senior vice president of product development, effective March 4, succeeding Dr. Behzad Khosrovi, who has retired after a 10-year career. Dr. Bley has more than 20 years of experience in the pharmaceutical industry, including management positions with increasing responsibility in research and product development. Before [...]

NovaBay’s NVC-422 aganocide renamed auriclosene

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) announced that the World Health Organization has approved the international nonproprietary name (INN) of auriclosene for the company’s lead aganocide compound, NVC-422. INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name. Aganocides are NovaBay’s first-in-class topical antimicrobial compounds, which are active against [...]

NovaBay partner expands trial to South Africa

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) partner Galderma S.A. has initiated the South African arm of its Phase 2b clinical study of a proprietary topical formulation of NVC-422 for the treatment of impetigo, a highly contagious skin infection that mainly affects infants and children. “The treatment of impetigo is a significant unmet need in South Africa, and the [...]

NovaBay introduces smartphone investor app

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) has launched its Mobile Shareholder Smartphone investor application available for free download through Apple’s App Store and Android’s Google Play. The InvestorApp provides users with the ability to quickly obtain NovaBay’s news, SEC filings, posters & publications, social media sites, media animations, the CEO’s Blog and financial information via smartphone [...]

NovaBay adds India to ophthamology study of pink eye

Tweet NovaBay Pharmaceuticals announced that the first patients have been enrolled in India into its global Phase 2b BAYnovation clinical study, investigating NVC-422 Ophthalmic Solution as a treatment of adenoviral conjunctivitis, a highly contagious form of “pink eye” for which there is an unmet ocular medical need. BAYnovation is a multi-centered, randomized clinical study expected [...]

NovaBay provides business update, 2013 outlook

Tweet NovaBay Pharmaceuticals (NYSE MKT:NBY) CEO Dr. Ron Najafi has provided a business update, highlighting recent accomplishments and outlook for 2013. Among other things, all three of the company’s Aganocide programs, in ophthalmology, dermatology, and urology, are currently in Phase 2 clinical trials, with data from the trials expected in 2013. At Sept. 30, 2012, [...]

NovaBay prices offering of shares and warrants

Tweet NovaBay Pharmaceuticals (AMEX:NBY) has priced an underwritten public offering of 5.9 million shares at a price of $1.25 a share, and one-year warrants to purchase up to 4,425,000 additional common shares. Net proceeds are expected to be about $6.34-million, excluding the exercise of any warrants. If the warrants are exercised in full, NovaBay would [...]

Next Page »